About Ironwood Pharmaceuticals (NASDAQ:IRWD)
Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout in adults under the ZURAMPIC and DUZALLO names. Ironwood Pharmaceuticals, Inc. has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal (GI) conditions in North America, China, Hong Kong, and Macau; and a license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in Japan. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:IRWD
CUSIP46333X10
Phone617-621-7722
Debt
Debt-to-Equity Ratio40.25%
Current Ratio4.72%
Quick Ratio4.71%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$298.28 million
Price / Sales8.74
Cash FlowN/A
Price / CashN/A
Book Value$0.07 per share
Price / Book246.86
Profitability
EPS (Most Recent Fiscal Year)($0.93)
Net Income$-116,930,000.00
Net Margins-39.20%
Return on Equity-2,073.20%
Return on Assets-21.05%
Miscellaneous
Employees730
Outstanding Shares150,900,000
Ironwood Pharmaceuticals (NASDAQ:IRWD) Frequently Asked Questions
What is Ironwood Pharmaceuticals' stock symbol?
Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD."
How were Ironwood Pharmaceuticals' earnings last quarter?
Ironwood Pharmaceuticals (NASDAQ:IRWD) announced its quarterly earnings results on Thursday, February, 15th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.18) by $0.04. The biotechnology company earned $94.20 million during the quarter, compared to analyst estimates of $88.86 million. Ironwood Pharmaceuticals had a negative return on equity of 2,073.20% and a negative net margin of 39.20%. The firm's quarterly revenue was up 7.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.12) EPS. View Ironwood Pharmaceuticals' Earnings History.
When is Ironwood Pharmaceuticals' next earnings date?
What price target have analysts set for IRWD?
10 Wall Street analysts have issued 12 month price targets for Ironwood Pharmaceuticals' stock. Their predictions range from $13.00 to $25.00. On average, they anticipate Ironwood Pharmaceuticals' stock price to reach $18.1250 in the next year. View Analyst Ratings for Ironwood Pharmaceuticals.
Who are some of Ironwood Pharmaceuticals' key competitors?
Some companies that are related to Ironwood Pharmaceuticals include Sarepta Therapeutics (SRPT), Agios Pharmaceuticals (AGIO), Gal�pagos (GLPG), United Therapeutics (UTHR), Hutchison China MediTech (HCM), Taro Pharmaceutical Industries (TARO), Loxo Oncology (LOXO), FibroGen (FGEN), GW Pharmaceuticals (GWPH), Advanced Accelerator Application (AAAP), Blueprint Medicines (BPMC), Ligand Pharmaceuticals (LGND), Array BioPharma (ARRY), Tesaro (TSRO), Ultragenyx Pharmaceutical (RARE), Emergent BioSolutions (EBS), Amicus Therapeutics (FOLD) and Ascendis Pharma (ASND).
Who are Ironwood Pharmaceuticals' key executives?
Ironwood Pharmaceuticals' management team includes the folowing people:
- Dr. Peter M. Hecht, Co-Founder, CEO & Director (Age 54)
- Dr. Mark G. Currie, Chief Scientific Officer, Pres of R&D and Sr. VP (Age 63)
- Ms. Halley E. Gilbert, Sr. VP, Chief Legal Officer & Sec. (Age 48)
- Mr. Thomas A. McCourt, Sr. VP of Marketing & Sales and Chief Commercial Officer (Age 61)
- Mr. Brian M. Cali Ph.D., Co-Founder and Sr. VP of R&D Strategy & External Innovation
Has Ironwood Pharmaceuticals been receiving favorable news coverage?
Media headlines about IRWD stock have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Ironwood Pharmaceuticals earned a media sentiment score of 0.15 on Accern's scale. They also assigned media stories about the biotechnology company an impact score of 46.40 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
How do I buy shares of Ironwood Pharmaceuticals?
Shares of IRWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ironwood Pharmaceuticals' stock price today?
One share of IRWD stock can currently be purchased for approximately $17.28.
How big of a company is Ironwood Pharmaceuticals?
Ironwood Pharmaceuticals has a market capitalization of $2.61 billion and generates $298.28 million in revenue each year. The biotechnology company earns $-116,930,000.00 in net income (profit) each year or ($0.93) on an earnings per share basis. Ironwood Pharmaceuticals employs 730 workers across the globe.
How can I contact Ironwood Pharmaceuticals?
Ironwood Pharmaceuticals' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-621-7722 or via email at [email protected]
MarketBeat Community Rating for Ironwood Pharmaceuticals (IRWD)
MarketBeat's community ratings are surveys of what our community members think about Ironwood Pharmaceuticals and other stocks. Vote "Outperform" if you believe IRWD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IRWD will underperform the S&P 500 over the long term. You may vote once every thirty days.
Ironwood Pharmaceuticals (NASDAQ:IRWD) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
10 Wall Street analysts have issued ratings and price targets for Ironwood Pharmaceuticals in the last 12 months. Their average twelve-month price target is $18.1250, suggesting that the stock has a possible upside of 4.89%. The high price target for IRWD is $25.00 and the low price target for IRWD is $13.00. There are currently 1 sell rating, 5 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Buy |
| Consensus Rating Score: | 2.30 | 2.22 | 2.27 | 2.50 |
| Ratings Breakdown: | 1 Sell Rating(s)
5 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
5 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
6 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $18.1250 | $17.2857 | $17.5556 | $18.2857 |
| Price Target Upside: | 4.89% upside | 13.72% upside | 15.50% upside | 22.56% upside |
Ironwood Pharmaceuticals (NASDAQ:IRWD) Consensus Price Target History
Ironwood Pharmaceuticals (NASDAQ:IRWD) Analyst Ratings History
Show:
(Data available from 4/22/2016 forward)
Ironwood Pharmaceuticals (NASDAQ:IRWD) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Ironwood Pharmaceuticals (NASDAQ IRWD) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 7.63%
Ironwood Pharmaceuticals (NASDAQ IRWD) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/5/2018 | Julie Mchugh | Director | Sell | 1,500 | $14.06 | $21,090.00 | 77,908 |  |
| 2/21/2018 | Gina Consylman | CFO | Sell | 3,594 | $14.66 | $52,688.04 | 59,125 | |
| 2/21/2018 | Mark G Currie | Insider | Sell | 1,634 | $14.66 | $23,954.44 | 18,124 | |
| 1/24/2018 | Mark G Currie | Insider | Sell | 60,000 | $15.45 | $927,000.00 | 835,000 | |
| 12/7/2017 | Peter M Hecht | CEO | Sell | 113,405 | $15.12 | $1,714,683.60 | 4,696,917 | |
| 12/4/2017 | Julie Mchugh | Director | Sell | 1,500 | $16.45 | $24,675.00 | 79,408 | |
| 11/10/2017 | Gina Consylman | CFO | Sell | 864 | $15.20 | $13,132.80 | | |
| 9/5/2017 | Julie Mchugh | Director | Sell | 1,500 | $16.16 | $24,240.00 | 80,908 | |
| 8/18/2017 | Gina Consylman | Insider | Sell | 207 | $14.34 | $2,968.38 | 52,865 | |
| 6/22/2017 | Halley E Gilbert | Insider | Sell | 35,000 | $19.75 | $691,250.00 | 35,000 | |
| 5/15/2017 | Thomas A Mccourt | Insider | Sell | 30,000 | $18.20 | $546,000.00 | 30,000 | |
| 2/14/2017 | Halley E Gilbert | Insider | Sell | 37,385 | $16.75 | $626,198.75 | 37,385 | |
| 1/12/2017 | Peter M Hecht | CEO | Sell | 65,987 | $15.67 | $1,034,016.29 | 4,703,315 | |
| 12/5/2016 | Lawrence S Olanoff | Director | Sell | 3,200 | $15.68 | $50,176.00 | 26,105 | |
| 9/6/2016 | Lawrence S Olanoff | Director | Sell | 3,200 | $13.72 | $43,904.00 | 29,305 | |
| 8/19/2016 | Gina Consylman | Insider | Sell | 207 | $13.54 | $2,802.78 | 21,123 | |
| 6/3/2016 | Lawrence S Olanoff | Director | Sell | 2,200 | $12.92 | $28,424.00 | 32,505 | |
| 5/25/2016 | Halley E Gilbert | Insider | Sell | 20,275 | $12.19 | $247,152.25 | 5,865 | |
| 3/11/2016 | Peter M Hecht | CEO | Sell | 120,000 | $10.72 | $1,286,400.00 | 4,710,322 | |
| 3/7/2016 | Lawrence S Olanoff | Director | Sell | 2,200 | $11.11 | $24,442.00 | 11,031 | |
| 2/24/2016 | Edward P Owens | Director | Buy | 10,000 | $8.32 | $83,200.00 | 144,006 | |
| 2/24/2016 | Gina Consylman | CAO | Sell | 420 | $8.50 | $3,570.00 | 6,330 | |
| 2/24/2016 | Mark G Currie | Insider | Sell | 152,154 | $8.53 | $1,297,873.62 | 25,558 | |
| 2/24/2016 | Thomas Graney | CFO | Sell | 563 | $8.50 | $4,785.50 | 5,137 | |
| 12/15/2015 | Peter M. Hecht | CEO | Sell | 73,418 | $11.07 | $812,737.26 | | |
| 12/7/2015 | Lawrence S Olanoff | Director | Sell | 2,200 | $11.77 | $25,894.00 | 13,231 | |
| 9/4/2015 | Lawrence S Olanoff | Director | Sell | 3,725 | $10.97 | $40,863.25 | 15,431 | |
| 3/17/2015 | Peter M Hecht | CEO | Sell | 200,000 | $15.62 | $3,124,000.00 | | |
| 3/12/2015 | Joseph C Cook Jr | Director | Sell | 5,883 | $15.54 | $91,421.82 | | |
| 3/10/2015 | Bryan E Roberts | Director | Sell | 95,998 | $15.20 | $1,459,169.60 | | |
| 3/3/2015 | Peter M Hecht | CEO | Sell | 63,442 | $15.75 | $999,211.50 | | |
| 2/20/2015 | Joseph C Cook Jr | Director | Sell | 35,500 | $15.60 | $553,800.00 | | |
| 12/15/2014 | Bryan E Roberts | Director | Sell | 19,792 | $15.20 | $300,838.40 | | |
| 6/12/2014 | Bryan E Roberts | Director | Sell | 200,000 | $14.24 | $2,848,000.00 | | |
| 5/29/2014 | Michael J Higgins | COO | Sell | 50,000 | $14.56 | $728,000.00 | | |
| 5/22/2014 | Mark Currie | Insider | Sell | 25,000 | $13.93 | $348,250.00 | 2,166 | |
| 4/24/2014 | Mark Currie | Insider | Sell | 25,000 | $11.67 | $291,750.00 | 2,166 | |
| 1/23/2014 | Mark Currie | Insider | Sell | 20,000 | $14.38 | $287,600.00 | 2,166 | |
| 1/14/2014 | Bryan Roberts | Director | Sell | 21,200 | $12.57 | $266,484.00 | | |
| 1/13/2014 | Bryan Roberts | Director | Sell | 823,350 | $12.71 | $10,464,778.50 | | |
| 1/6/2014 | Bryan Roberts | Director | Sell | 55,450 | $12.01 | $665,954.50 | | |
| 11/7/2013 | Terrance Mcguire | Director | Sell | 2,083 | $9.11 | $18,976.13 | 2,915 | |
| 6/17/2013 | Michael J Higgins | COO | Sell | 150,000 | $11.74 | $1,761,000.00 | | |
| 3/11/2013 | Thomas A Mccourt | Insider | Sell | 40,000 | $17.00 | $680,000.00 | | |
| 11/5/2012 | Peter M Hecht | CEO | Buy | 50,000 | $11.65 | $582,500.00 | | |
| 10/8/2012 | Fmr Llc | Insider | Sell | 19,305 | $13.02 | $251,351.10 | | |
(Data available from 1/1/2013 forward)
Ironwood Pharmaceuticals (NASDAQ IRWD) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Ironwood Pharmaceuticals (IRWD) Earns Buy Rating from Analysts at Berenberg Bank
www.americanbankingnews.com - April 19 at 3:36 PM |
| Ironwood Pharmaceuticals (IRWD) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - April 18 at 12:50 PM |
 | Ironwood Pharmaceuticals to Host First Quarter 2018 Investor Update Call
finance.yahoo.com - April 17 at 5:12 PM |
| Ironwood Pharmaceuticals (IRWD) Lowered to "Hold" at BidaskClub
www.americanbankingnews.com - April 16 at 8:07 PM |
| Ironwood Pharmaceuticals (IRWD) Cut to Sell at ValuEngine
www.americanbankingnews.com - April 15 at 10:59 AM |
| Ironwood Pharmaceuticals (IRWD) Downgraded to "Strong Sell" at BidaskClub
www.americanbankingnews.com - April 11 at 9:30 PM |
| Ironwood Pharmaceuticals Sees Unusually Large Options Volume (IRWD)
www.americanbankingnews.com - April 11 at 7:04 AM |
 | Activist investor Denner targets Cambridge’s Ironwood, lifting shares
www.bizjournals.com - April 10 at 4:47 PM |
| Ironwood Pharmaceuticals (IRWD) Upgraded at ValuEngine
www.americanbankingnews.com - April 10 at 12:33 AM |
 | Ironwood Pharma (IRWD) Announces Director Nomination from Sarissa Capital
www.streetinsider.com - April 9 at 4:43 PM |
 | Ironwood investor Sarissa Capital to nominate board member
seekingalpha.com - April 9 at 4:43 PM |
| Ironwood Pharmaceuticals (IRWD) Given a $18.00 Price Target by Wells Fargo Analysts
www.americanbankingnews.com - April 9 at 3:30 PM |
| Ironwood Pharmaceuticals Announces Director Nomination from Sarissa Capital
finance.yahoo.com - April 9 at 9:15 AM |
| Ironwood Pharmaceuticals (IRWD) Lowered to "Sell" at ValuEngine
www.americanbankingnews.com - April 8 at 11:49 AM |
| Ironwood Pharmaceuticals, Inc. (IRWD) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - March 31 at 5:36 AM |
| Ironwood Pharmaceuticals (IRWD) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - March 29 at 10:49 PM |
| Ironwood Pharmaceuticals Sees Unusually High Options Volume (IRWD)
www.americanbankingnews.com - March 28 at 7:22 AM |
| Ironwood Pharmaceuticals (IRWD) Upgraded to Buy by BidaskClub
www.americanbankingnews.com - March 27 at 4:34 PM |
| Ironwood Pharmaceuticals (IRWD) Downgraded by BidaskClub
www.americanbankingnews.com - March 27 at 3:28 PM |
| Ironwood Pharmaceuticals (IRWD) Presents At Barclays Global Healthcare Conference 2018 - Slideshow
seekingalpha.com - March 16 at 9:16 AM |
| Ironwood Pharmaceuticals (IRWD) Presents At 38th Annual Cowen and Company Healthcare Conference - Slideshow
seekingalpha.com - March 12 at 5:50 PM |
| Short Interest in Ironwood Pharmaceuticals, Inc. (IRWD) Grows By 7.6%
www.americanbankingnews.com - March 11 at 1:58 AM |
| Head to Head Analysis: Ironwood Pharmaceuticals (IRWD) & Senomyx (SNMX)
www.americanbankingnews.com - March 8 at 5:24 AM |
| Ironwood Pharmaceuticals, Inc. (IRWD) Director Julie Mchugh Sells 1,500 Shares
www.americanbankingnews.com - March 6 at 9:58 PM |
| What’s The Market Sentiment Around Loss-Making Ironwood Pharmaceuticals Inc (NASDAQ:IRWD)?
finance.yahoo.com - March 6 at 5:04 PM |
| Ironwood Pharmaceuticals, Inc. (IRWD) Shares Bought by Swiss National Bank
www.americanbankingnews.com - March 6 at 3:08 PM |
| Ironwood Pharmaceuticals, Inc. (IRWD) Shares Bought by Senzar Asset Management LLC
www.americanbankingnews.com - March 5 at 3:45 PM |
| Contrasting Ironwood Pharmaceuticals (IRWD) & Infinity Pharmaceuticals (INFI)
www.americanbankingnews.com - February 24 at 7:22 PM |
| State of Wisconsin Investment Board Has $12.69 Million Position in Ironwood Pharmaceuticals, Inc. (IRWD)
www.americanbankingnews.com - February 24 at 7:09 AM |
| Insider Selling: Ironwood Pharmaceuticals, Inc. (IRWD) Insider Sells 1,634 Shares of Stock
www.americanbankingnews.com - February 22 at 7:26 PM |
| Ironwood Pharmaceuticals, Inc. (IRWD) CFO Sells $52,688.04 in Stock
www.americanbankingnews.com - February 22 at 7:08 PM |
 | Ironwood (IRWD) Beats Estimates in Q4 Earnings, Stock Up
www.zacks.com - February 16 at 8:52 AM |
| Today’s Research Reports on Stocks to Watch: Ironwood Pharmaceuticals and Teva Pharmaceutical
finance.yahoo.com - February 16 at 8:52 AM |
| Ironwood beats Street 4Q forecasts
finance.yahoo.com - February 15 at 4:50 PM |
| Ironwood Pharmaceuticals (IRWD) Posts Quarterly Earnings Results
www.americanbankingnews.com - February 15 at 11:40 AM |
| Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2017 Investor Update
finance.yahoo.com - February 15 at 8:30 AM |
| $86.24 Million in Sales Expected for Ironwood Pharmaceuticals, Inc. (IRWD) This Quarter
www.americanbankingnews.com - February 15 at 3:34 AM |
| Ironwood Pharmaceuticals Inc’s (NASDAQ:IRWD) Earnings Dropped -73.31%, Did Its Industry Show Weakness Too?
finance.yahoo.com - February 14 at 9:24 AM |
| Ironwood Pharmaceuticals, Inc. (IRWD) Expected to Post Earnings of -$0.21 Per Share
www.americanbankingnews.com - February 13 at 11:14 PM |
| Ironwood Pharmaceuticals (IRWD) to Release Earnings on Monday
www.americanbankingnews.com - February 12 at 3:02 AM |
| Ironwood Pharmaceuticals (IRWD) Upgraded to Sell at BidaskClub
www.americanbankingnews.com - February 11 at 6:22 AM |
| Ironwood Pharmaceuticals, Inc. (IRWD) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - February 9 at 5:24 AM |
| Repros Therapeutics (RPRX) & Ironwood Pharmaceuticals (IRWD) Critical Comparison
www.americanbankingnews.com - February 5 at 10:24 AM |
| Wedbush Equities Analysts Reduce Earnings Estimates for Ironwood Pharmaceuticals, Inc. (IRWD)
www.americanbankingnews.com - February 2 at 9:08 AM |
| Brokers Set Expectations for Ironwood Pharmaceuticals, Inc.'s FY2021 Earnings (IRWD)
www.americanbankingnews.com - February 1 at 4:22 PM |
| Ironwood Pharmaceuticals to Host Fourth Quarter and Full-Year 2017 Investor Update Call
finance.yahoo.com - February 1 at 4:11 PM |
| $86.70 Million in Sales Expected for Ironwood Pharmaceuticals, Inc. (IRWD) This Quarter
www.americanbankingnews.com - January 29 at 2:18 AM |
| Zacks: Analysts Expect Ironwood Pharmaceuticals, Inc. (IRWD) to Post -$0.18 EPS
www.americanbankingnews.com - January 27 at 11:16 PM |
| Mark G. Currie Sells 60,000 Shares of Ironwood Pharmaceuticals, Inc. (IRWD) Stock
www.americanbankingnews.com - January 26 at 9:10 PM |
 | Interesting IRWD Put And Call Options For March 16th
www.nasdaq.com - January 25 at 4:12 PM |
Ironwood Pharmaceuticals (NASDAQ:IRWD) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Ironwood Pharmaceuticals (NASDAQ:IRWD) Income Statement, Balance Sheet and Cash Flow Statement
Ironwood Pharmaceuticals (NASDAQ IRWD) Stock Chart for Sunday, April, 22, 2018
Loading chart…
